Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label, multi-center trial investigating zalutumumab, a human monoclonal anti-EGF [epithelial growth factor] receptor antibody, in combination with chemo-radiation in stage IIIA-IIIB non small cell lung cancer patients

Next Previous
X
Search
Trial Profile

A randomized, open-label, multi-center trial investigating zalutumumab, a human monoclonal anti-EGF [epithelial growth factor] receptor antibody, in combination with chemo-radiation in stage IIIA-IIIB non small cell lung cancer patients

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zalutumumab (Primary) ; Cisplatin; Docetaxel
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Large cell carcinoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Genmab

    • Most Recent Events

    • 05 Dec 2011 Actual patient number is 13 according to ClinicalTrials.gov.
    • 28 Oct 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Jul 2008 The expected completion date for this trial is now 1 Sep 2012, according to Clinicaltrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top